Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am J Cardiol. 1995 Oct 1;76(10):699-701.
Daniels SR, Kimball TR, Morrison JA, Khoury P, Witt S, Meyer RA Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological, and clinical significance. Circulation. 1995 Dec 1;92(11):3249-54.
Daniels SR, Lipman MJ, Burke MJ, Loggie JM Determinants of retinal vascular abnormalities in children and adolescents with essential hypertension. J Hum Hypertens. 1993 Jun;7(3):223-8.
Daniels SR, Lipman MJ, Burke MJ, Loggie JM The prevalence of retinal vascular abnormalities in children and adolescents with essential hypertension. Am J Ophthalmol. 1991 Feb 15;111(2):205-8.
Daniels SR, Loggie JM, Khoury P, Kimball TR Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998 May 19;97(19):1907-11.
Daniels SR, Meyer RA, Liang YC, Bove KE Echocardiographically determined left ventricular mass index in normal children, adolescents and young adults. J Am Coll Cardiol. 1988 Sep;12(3):703-8.
Daniels SR, Strife CF, Dolan LM, Loggie JM Distribution and correlates of creatinine clearance in children and adolescents with blood pressure elevation. J Pediatr. 1993 Jun;122(6):S68-73.
Kimball TR, Daniels SR, Loggie JM, Khoury P, Meyer RA Relation of left ventricular mass, preload, afterload and contractility in pediatric patients with essential hypertension. J Am Coll Cardiol. 1993 Mar 15;21(4):997-1001.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
